BAL Pharma reports H1FY22 results with 290% growth in PAT, led by strong performance of its API business
With this, BAL Pharma further consolidates its market share in Diabetes as a Therapeutic segment Domestic to exports was at 3070 in H1FY22 versus 2575 in H1FY21. Order book for FDF stands at INR 200mn as on H1FY22.
BENGALURU, India, Nov. 15, 2021 /PRNewswire/ -- BAL Pharma, a fully integrated pharmaceutical company specialized in Prescription Drugs, Generics, pharma intermediates, and Bulk Actives has announced its results for the second quarter and half year ended on 30th September 2021.
Financial Highlights – Q2 & H1FY22 Standalone Financial INR Mn Q2FY22 Q2FY21 YoY H1FY22 H1FY21 YoY Revenue 679.1 646.6 5% 1390.5 1172.1 19% EBITDA 73.1 78 -6% 150.5 140.1 7% PAT 30.5 15.3 99% 45.8 31.7 44% The Company has delivered an all-round performance for H1FY22 with Revenue registering a growth of 19%, EBITDA grew by 7% and PAT grew by 44%. Companies API's business has been witnessing strong momentum which is driving overall growth of its standalone business. Company's standalone business comprises of majority of operating business.
Consolidated Financials INR Mn Q2FY22 Q2FY21 YoY H1FY22 H1FY21 YoY Revenue 677.3 646.2 5% 1386.9 1169 19% EBITDA 68.8 71.6 -4% 145 124 17% PAT 13.9 4.9 184% 30.4 7.8 290% EPS 0.97 0.3 223% 2.11 0.6 252% Financial Highlights- H1FY22 • Revenue- Strong contribution from API business led to Revenue growth of 19% YoY. Such overall Revenue growth was on account of non-covid therapeutic segments and robust demand both in the domestic and international markets.
• EBITDA increased by 17% YoY to INR 145 mn in H1FY22. EBITDA margins remained stable at 10.5%, Although bottlenecks on supply chain logistics have been gradually reducing, higher freight rates and higher Raw material costs kept EBITDA margin under check. As a result, Gross margins have witnessed softening of 200bps YoY in H1FY22.
• PAT increased by 290% YoY to INR 30.4mn in H1FY22. Better operating leverage and lower overheads led to overall increase in PAT. Company has reduced their debt in H1FY22 which resulted into lower interests costs – down by 6% YoY in H1FY22 and by 18% YoY in Q2FY22.
API Business: • API segment revenue reported an increase of 45% YoY to INR 818.1 mn in H1FY22. Share of API in total revenue increase to 60% in H1FY22 from 49% in H1FY21.
• Exports: Domestic mix was 64:36 in H1FY22 versus 44:66 in H1FY21.
• Gliclazide being an API used for treating Diabetes has been an important contributor in the company's earnings. Top 5 API's contributed nearly 94% of API's revenue in H1FY22.
Formulations Business: • Formulations segment remained marginally subdued at INR 552mn in H1FY22. However, Domestic Formulations have been witnessing positive momentum and has reported 13% growth YoY.
• On the domestic front, the company is in the process of launching Dapagliflozin under the brand name Dapaten which is an anti-diabetic drug. With this, BAL Pharma further consolidates its market share in Diabetes as a Therapeutic segment • Domestic to exports was at 30:70 in H1FY22 versus 25:75 in H1FY21.
• Order book for FDF stands at INR 200mn as on H1FY22. With the new launches and strengthening medical representative team in domestic market would continue the positive trajectory of domestic formulations market.
Commenting on financial results, Mr. Shailesh Siroya, Managing Director, BAL Pharma said, ''The financial performance for H1FY22 has been quite encouraging for especially on API front. Post easing of Covid related supply chain and logistical issues, the company has been able to report a strong recovery in growth. On API front, export markets were quite buoyant and has witnessed significant improvement over previous year. The Company would keep focussing on key therapeutic areas affecting Lifestyle disorders, and Exports are expected to drive the growth momentum going head.'' ''It was tactically decided to restrict export of formulations in Q2FY22 due to unfavourable market conditions. Higher raw material costs, freight costs made it uneconomical to take FDF export orders. On Formulations front, company has been continuously focussing on improving Domestic market share. Domestic formulations market has been improving traction on continuous basis. Domestic FDF grew by 13% for H1FY22 and 16% QoQ basis. Company has laid out an outlay to improve market share in domestic formulations market by strengthening medical representative team and have new product launches over period of time. BAL Pharma plans to launch Gliclazide MR 30 and 60 mg in the EU market, and is expected to file dossier in Q1FY23. Though Africa and Latin America remains the dominant market for export formulations, the company is targeting increasing its presence in various other geographies like Southeast Asia and CIS countries.'' ''Our Strategy over medium to long-term remains to focus on API exports and Domestic formulations and simultaneously strengthening our balance sheet as well. Our product opportunities are encouraging and we expect demand to remain buoyant going ahead in the current fiscal year''.
About BAL Pharma Ltd (BPL) BAL Pharma Limited (BSE: 524824) (NSE: BALPHARMA) is a fully integrated pharmaceutical company specialized in Prescription Drugs, Generics, pharma intermediates and Bulk Actives. BAL Pharma's focused therapeutic areas are oncology, diabetes, gastroenterology, and dermatology, The Company is one of the largest producers and exporters of Gliclazide, a medicine to treat type-2 diabetes. BAL Pharma's niche APIs and FDFs are produced at world class manufacturing facilities located at Karnataka, Maharashtra, Rajasthan and Uttarakhand. The Company exports APIs to Europe, Australia, Japan, Far East, Canada, Latin America, Africa, Middle East and other World markets. Its FDFs are exported to Semi-regulated, Non-regulated market, and a select regulated market, besides having a robust domestic presence. Backed by strength in Research and Development, and strong infrastructure, BAL Pharma is poised to become a significant company in the pharmaceutical industry.
Forward-Looking Statement: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. BAL Pharma Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)